Stockreport

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesion [Read more]